Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Accumulated Expenses (2017 - 2025)

Historic Other Accumulated Expenses for UroGen Pharma (URGN) over the last 9 years, with Q3 2025 value amounting to $5.0 million.

  • UroGen Pharma's Other Accumulated Expenses rose 2170.39% to $5.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 million, marking a year-over-year increase of 2170.39%. This contributed to the annual value of $7.9 million for FY2024, which is 10590.67% up from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Other Accumulated Expenses is $5.0 million, which was up 2170.39% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Other Accumulated Expenses ranged from a high of $7.9 million in Q4 2024 and a low of $1.7 million during Q1 2021
  • Its 5-year average for Other Accumulated Expenses is $3.7 million, with a median of $3.6 million in 2023.
  • In the last 5 years, UroGen Pharma's Other Accumulated Expenses surged by 13106.63% in 2022 and then tumbled by 2055.38% in 2023.
  • UroGen Pharma's Other Accumulated Expenses (Quarter) stood at $3.3 million in 2021, then decreased by 1.62% to $3.3 million in 2022, then grew by 17.83% to $3.9 million in 2023, then soared by 105.91% to $7.9 million in 2024, then plummeted by 37.63% to $5.0 million in 2025.
  • Its Other Accumulated Expenses stands at $5.0 million for Q3 2025, versus $4.9 million for Q2 2025 and $4.7 million for Q1 2025.